Start / PharmaTalkRadio / Advancing bispecifics for combination immunotherapy

PharmaTalkRadio

Advancing Bispecifics for Combination Immunotherapy

43 min • 2 mars 2020

First recorded at the fourth annual IO Combinations 360° conference, this panel moderated by Dr Daniel Chen, IGM Biosciences discusses advancing bispecifics for combination immunotherapy. This discussion covers the following topics: What are the types of bispecifics and what are the limitations?What are the toxicity related side effects?What are teh next steps/levels for bispecifics?What does the future hold for bispecifics? Panelists include: Julie Bailis, PhD, AmgenRajkumar Ganesan, PhD, Janssen Research & DevelopmentDavid Schaer, PhD, Pfizer To learn more about the 5th annual IO Combinations 360° conference please visit www.iocombinations360.com

Senaste avsnitt

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

25 juli | 29 min

Catalyzing Change: The Business Imperative of Patient-Centric Drug Development

21 juli | 26 min

How Emerging Biopharma CMOs Can Better Partner with Patient Organizations

21 juli | 32 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00